Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon Alemany

Showing results (41-50 of 101) with videos related to

Pageof 11
Sort By:
Oncotarget|February 11, 2017
A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxelAna Mato-Berciano, Giulia Raimondi, Maria Victoria Maliandi, et al.
Human Gene Therapy|March 4, 2014
Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the fieldDragomira Majhen, Hugo Calderon, Naresh Chandra, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 21, 2007
Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathwayManel Cascallo, Marta M Alonso, Juan J Rojas, et al.
Journal of Medical Virology|May 26, 2018
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse modelLukasz Kuryk, Anne-Sophie W Møller, Mariangela Garofalo, et al.
Plos One|October 27, 2011
Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosingDaniel Abate-Daga, Nuria Andreu, Juan Camacho-Sánchez, et al.
Cancer Research|November 1, 2008
Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potencyAlena Gros, Jordi Martínez-Quintanilla, Cristina Puig, et al.
Molecular Therapy Oncolytics|August 11, 2021
Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulationMartí Farrera-Sal, Rafael Moreno, Ana Mato-Berciano, et al.
Journal for Immunotherapy of Cancer|January 27, 2019
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engagerJana de Sostoa, Carlos Alberto Fajardo, Rafael Moreno, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 23, 2014
A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncologyEduardo Laborda, Cristina Puig-Saus, Alba Rodriguez-García, et al.
Journal of Translational Medicine|July 27, 2023
Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma modelsJessica Wenthe, Emma Eriksson, Ann-Charlotte Hellström, et al.
Pageof 11

Showing results (41-50 of 101) with videos related to

Sort By:
Pageof 11
Oncotarget|February 11, 2017
A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxelAna Mato-Berciano, Giulia Raimondi, Maria Victoria Maliandi, et al.
Human Gene Therapy|March 4, 2014
Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the fieldDragomira Majhen, Hugo Calderon, Naresh Chandra, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 21, 2007
Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathwayManel Cascallo, Marta M Alonso, Juan J Rojas, et al.
Journal of Medical Virology|May 26, 2018
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse modelLukasz Kuryk, Anne-Sophie W Møller, Mariangela Garofalo, et al.
Plos One|October 27, 2011
Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosingDaniel Abate-Daga, Nuria Andreu, Juan Camacho-Sánchez, et al.
Cancer Research|November 1, 2008
Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potencyAlena Gros, Jordi Martínez-Quintanilla, Cristina Puig, et al.
Molecular Therapy Oncolytics|August 11, 2021
Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulationMartí Farrera-Sal, Rafael Moreno, Ana Mato-Berciano, et al.
Journal for Immunotherapy of Cancer|January 27, 2019
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engagerJana de Sostoa, Carlos Alberto Fajardo, Rafael Moreno, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 23, 2014
A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncologyEduardo Laborda, Cristina Puig-Saus, Alba Rodriguez-García, et al.
Journal of Translational Medicine|July 27, 2023
Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma modelsJessica Wenthe, Emma Eriksson, Ann-Charlotte Hellström, et al.
Pageof 11